GenVivo, Inc.
Wednesday, June 05, 2024
Oncology
Company Presentation Theater 1
GenVivo was founded on the idea that we can effectively treat cancer patients with the latest gene delivery technologies. We are committed to enhancing the overall patient treatment experience.
We deliver innovative drugs to empower the patient’s own immune system to mount a targeted attack against cancer.
These therapies are off-the-shelf and come without the cost and time delays associated with personalized cancer vaccines. We are dedicated to providing accessible and efficient solutions that redefine the landscape of cancer treatment.
GenVivo is a fully-integrated. clinical stage company with in-house cGMP manufacturing for clinical drug product. Our lead candidate, GEN2, is in Phase I trials.
.png)
Company Website:
https://genvivoinc.com/
Lead Product in Development:
GEN2: IV administered, highly engineered vector encoding proprietary pro-drug facilitated cancer killing and immunocytokine genes.
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4
Company HQ City
San Marino
Company HQ State
CA
Company HQ Country
United States
CEO/Top Company Official
David H. Dornsife
Development Phase of Primary Product
Phase I
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())